Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in high-risk HR+/HER2- early breast cancer
NCT04565054Phase 3Active, not recruiting
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Sep 2020
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of abemaciclib in breast cancer, sponsored by Westdeutsche Studiengruppe. Started Sep 2020; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04565054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04565054.